Welcome to our dedicated page for Hca Healthcare SEC filings (Ticker: HCA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
HCA Healthcare filings document a NYSE-listed healthcare services company whose common stock is registered under Section 12(b) and whose wholly owned subsidiary, HCA Inc., issues senior unsecured notes guaranteed by the parent. Recent 8-K reports record quarterly operating results, dividends, share repurchase authorization, commercial paper and debt refinancing activity, and indenture supplements for senior notes.
Proxy and annual-meeting disclosures cover director elections, shareholder voting results, board matters, executive compensation, and performance award programs linked to EBITDA and quality measures. Registration and offering-related filings describe shelf registration use, prospectus supplements, note terms, guarantees, trustee arrangements and capital-structure disclosures for HCA's healthcare services operations.
HCA Healthcare, Inc. filed its annual report describing a large, diversified hospital and outpatient network and how it generates revenue. As of December 31, 2025, HCA operated 190 hospitals, 121 freestanding ambulatory surgery centers and 31 freestanding endoscopy centers across 19 U.S. states and England, with 50,436 licensed beds and 2,297,065 admissions.
For 2025, HCA reported $75.6 billion in revenues, with managed care and other insurers contributing $36.968 billion, Medicare $11.273 billion, Managed Medicare $13.435 billion, Medicaid and Managed Medicaid $9.602 billion, international payers $1.864 billion and other sources $2.458 billion. Outpatient revenues represented 38% of patient revenues. Operating metrics showed a 73% occupancy rate, 9.95 million emergency room visits, 1.02 million outpatient surgeries and 545,405 inpatient surgeries.
The report highlights a strategy focused on expanding in existing markets, enhancing clinical quality and digital and AI capabilities, and building comprehensive local networks. It also outlines extensive regulatory and reimbursement frameworks, including detailed Medicare, Medicaid, managed care and value-based payment models, as well as key risk factors such as significant indebtedness, workforce shortages, cybersecurity threats, evolving public health crises, shifting government policies, Medicaid reforms and intense competition from other hospitals, physician-owned facilities and not-for-profit systems.
HCA Healthcare SVP & Controller Christopher F. Wyatt reported equity transactions involving company stock. On February 5, 2026, he exercised 10,670 Stock Appreciation Rights at an exercise price of $139.06, receiving the same number of HCA common shares and bringing his direct holdings to 51,737 shares.
On the same date, a separate transaction coded "F" disposed of 5,674 common shares at a reported price of $513.76 per share, leaving Wyatt with 46,063 HCA common shares held directly. The underlying stock appreciation rights, which vested in four equal annual installments beginning January 30, 2020, are now fully exercised.
HCA Healthcare EVP and COO Jon M. Foster reported transactions in HCA common stock on February 5, 2026. He exercised a stock appreciation right covering 29,330 shares at an exercise price of $139.06, receiving that number of common shares.
On the same date, 16,076 shares of common stock were disposed of with a transaction code "F" at $513.76 per share, typically reflecting shares withheld to cover obligations, leaving 13,254 shares held directly. He also reports indirect ownership of HCA common stock, including 67,595 shares by JMF Trust, 72,308 shares by LCF Trust, 19,985 shares by JMF Family Trust, and 11,566 shares by a 2025 GRAT.
HCA Healthcare, Inc. senior vice president and Chief Nurse Executive Erica Rossitto reported her equity holdings as an officer of the company. She directly owns 9,149 shares of HCA common stock, along with restricted stock units covering 105 and 323 shares that convert into common stock as they vest beginning January 31, 2027. She also holds multiple stock appreciation rights grants over various share amounts, with exercise prices ranging from $81.96 to $482.53 and expiration dates between 2027 and 2036, many of which vest in four equal annual installments starting from specific past and future dates.
HCA Healthcare (HCA) CEO and director Samuel N. Hazen reported multiple open‑market sales of HCA common stock on February 3, 2026, at weighted average prices ranging from about $497.18 to $502.95 per share. After these sales, he directly held 32,276 shares of HCA common stock.
On February 4, 2026, Hazen reported a transfer of 1,045 shares at $498.35 per share to a trust under a power of substitution, in exchange for assets of equal value. The footnote states this was a change in the form of beneficial ownership and did not change the total number of HCA shares he may be deemed to beneficially own. Following the transfer, he directly held 31,231 shares and had additional indirect holdings through various trusts and a limited partnership, including 16,024 shares held by HD Trust and 813,320 shares held by an LP.
HCA Healthcare EVP and Chief Clinical Officer Michael S. Cuffe reported two transactions in HCA common stock on February 3, 2026. A transaction coded “S” showed the disposition of 1,500 shares at $498.0901 per share. A second transaction coded “G” reported 4,050 shares at $0 per share. After these transactions, he directly owned 25,952.9017 shares of HCA common stock.
HCA Healthcare, Inc. shareholder plans Rule 144 sale of shares
A shareholder has filed a notice of intent to sell 1,500 shares of HCA Healthcare common stock through Merrill Lynch on the NYSE. The filing lists an aggregate market value of $747,135.15 and indicates an approximate sale date of February 3, 2026.
The shares were acquired on April 29, 2021 through the exercise of a stock appreciation right from HCA Healthcare, described as a compensatory payment. The notice states that the person signing does not know of any undisclosed material adverse information about HCA Healthcare’s current or prospective operations.
HCA Healthcare, Inc. common stock: a shareholder has filed a Form 144 to sell 42,877 common shares through Merrill Lynch on the NYSE, with an aggregate market value of 21483273.66.
The shares were acquired on 01/30/2026 by exercising a stock appreciation right granted by HCA Healthcare, Inc., with compensatory payment as consideration. The planned sale date is approximately 02/03/2026, and the filing notes 228,193,900 common shares outstanding.
HCA Healthcare, Inc. reported that its SVP & Controller, Christopher F. Wyatt, received a grant of stock appreciation rights on January 29, 2026. The award covers 2,560 stock appreciation rights with an exercise price of $482.53 per share.
These stock appreciation rights vest in four equal annual installments beginning on January 29, 2027, and are exercisable through January 29, 2036. Following this grant, Wyatt beneficially holds 2,560 derivative securities directly.
HCA Healthcare executive Michael R. McAlevey reported a new equity award. On January 29, 2026, he received 8,067 stock appreciation rights linked to HCA common stock, held as a direct beneficial owner.
The stock appreciation rights carry a $482.53 exercise price and vest in four equal annual installments beginning on January 29, 2027, giving this executive a long-term, performance-linked incentive tied to HCA Healthcare’s share price over time.